Is FDA Reviewing A Biosimilar Marketing Application?
This article was originally published in The Pink Sheet Daily
The agency changes its rhetoric on the subject, inviting speculation about whether a marketing application has been received.
You may also be interested in...
Naming and labeling questions will likely be resolved with agency actions on pending biosimilar applications.
Celltrion’s biosimilar infliximab has won over J&J’s Remicade in Norway’s national drug procurement bidding, and will be priced at a 39% discount to the originator product.
The first biosimilar MAb approval in Canada could mean Korea’s Celltrion and its partner Hospira are getting closer to filing in the U.S.